Sanofi US and its consumer health business Chattem, Inc., have re-introduced Rolaids to stores across the United States. The iconic brand returns after a three-year hiatus in the marketplace and follows Chattem’s acquisition of Rolaids earlier this year.
“For the last few years there has been a significant gap in the over-the-counter antacid marketplace here in the US,” said Zan Guerry, chief executive officer, Chattem. “Starting today, the millions of people who suffer from frequent heartburn and acid indigestion can once again turn to Rolaids to help relieve their symptoms.”
Rolaids is sold in retail stores across the United States and is available in both tablets and a new liquid form. The liquid is a first for the brand, as is new Ultra Strength formulation in both tablets and liquid. Ultra Strength Tablets and Liquid deliver Rolaids' strongest level of acid neutralization.
“Incorporating Rolaids into Chattem’s portfolio further strengthens Sanofi’s position as a leader in the US consumer healthcare sector and helps to further diversify our category offerings,” said Anne Whitaker, president, North America Pharmaceuticals, Sanofi.
Heartburn occurs when the opening between the stomach and esophagus malfunctions and allows stomach acid to enter the esophagus. Chattem completed the acquisition of the worldwide rights to the Rolaids brand from McNeil Consumer Healthcare Division of McNEIL-PPC, Inc. on January 7, 2013.
Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. The company has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.